Pulse Biosciences, Inc. is a bioelectric medicine company focused on developing its Nanosecond Pulsed-Field Ablation (nsPFA) technology. The company's core platform, the nPulse System, delivers ultra-short electrical pulses to induce cell death without generating significant heat, thereby sparing surrounding non-cellular tissue structures. Pulse Biosciences is advancing multiple clinical applications, including the nPulse Cardiac Surgical Clamp and nPulse Cardiac Catheter System for the treatment of atrial fibrillation. Additionally, the company offers the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical settings. Originally incorporated as Electroblate, Inc. in 2014, the company operates out of Miami, Florida, and aims to provide therapeutic alternatives to traditional thermal ablation methods.
